Jamie Pearson of New Holland Group explains why the current European market is medical first, why EU GMP capability is becoming strategic infrastructure, and why expansion exposes operating weakness instead of fixing it.

How will Schedule 3 affect the medical market versus the adult-use market? Or US imports to Europe?

Jamie Pearson provides insight into how new regulations might impact cannabis crossing borders.

What does US federal cannabis policy mean for the rest of the world? Global strategist Jamie Pearson breaks it down and explains why most companies aren’t ready.